MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Halozyme Therapeutics Inc

Închisă

SectorSănătate

61.86 -1.86

Rezumat

Modificarea prețului

24h

Curent

Minim

61.13

Maxim

63.04

Indicatori cheie

By Trading Economics

Venit

1K

137M

Vânzări

7.9M

298M

P/E

Medie Sector

18.604

63.778

EPS

1.26

Marjă de profit

45.976

Angajați

350

EBITDA

13M

203M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+7.11% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

690M

7.9B

Deschiderea anterioară

63.72

Închiderea anterioară

61.86

Sentimentul știrilor

By Acuity

50%

50%

180 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Halozyme Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 mar. 2025, 19:42 UTC

Top știri

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5 mar. 2025, 10:30 UTC

Top știri

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

1 nov. 2024, 11:30 UTC

Top știri

S&P 500 Futures Climb In Premarket Trading; Atlassian, XP Lead

Comparație

Modificare preț

Halozyme Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

7.11% sus

Prognoză pe 12 luni

Medie 67.5 USD  7.11%

Maxim 78 USD

Minim 53 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHalozyme Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

8 ratings

5

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

62.85 / 63.8825Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

180 / 386 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.